British drug major AstraZeneca Plc. reported Thursday that its third-quarter profit more than doubled from last year, benefited by higher product sales mainly in Oncology. Looking ahead for fiscal 2020, the company maintained full-year guidance. In separate developments, the European Union has approved AstraZeneca's Forxiga (dapagliflozin) for the treatment of symptomatic chronic heart failure.
from RTT - Earnings https://ift.tt/3mTpbD7
via IFTTT
No comments:
Post a Comment